Company intelligence / Profile preview

CytoMed Therapeutics China

Singapore, Singaporecytomed.sg ↗
Ownership
Private
Employees
~25
Development stage
Other
01

Overview

CytoMed Therapeutics is a Singapore-based clinical-stage biopharmaceutical company developing donor-derived allogeneic cell therapies. Its lead CAR-γδ T cell product CTM-N2D is in a first-in-human Phase I trial in Singapore for advanced solid and blood cancers, with a Phase II investigator-initiated trial planned in India. Early dosing in the ANGELICA trial has been completed, with initial safety readout expected around end-2025.[1][3][4][6]

Therapeutic areas
HematologyImmunologyNeurologyRheumatologyOncology
Modalities
Cell therapyCAR-T cell therapyNK cell therapyStem cell therapyInduced pluripotent stem cell derived therapy
Industry
Biotech
02

Drug pipeline

4 assets

cord blood-derived mesenchymal stromal cells

2

3 more assets in the full pipeline.

03

Partnerships

SunAct Cancer Institute Private Limited (India) – Phase II IIT using CytoMed-manufactured gamma delta T cells for various cancers[1][6]Hangzhou CNK Therapeutics Co., Ltd (China) – MOU to use PiggyBac non-viral gene editing for CAR integration and potential China JV for clinical trials[5]Sengkang General Hospital (Singapore) – research collaboration on injectable umbilical cord-derived mesenchymal stem cells for cartilage diseases and osteoarthritis[4][6]

Beyond the preview

Go deeper on CytoMed Therapeutics China.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoMed Therapeutics China.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call